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Abstract
Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a
history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2
conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and
nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive C-
reactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII)
were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥50 years and with ≥10
pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were
recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide
measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were
determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers
(control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found
nonreversible airflow limitation in 34% of patients with CHF. On the other hand, COPD patients had higher plasma
levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p < 0.05). None of the
inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD
patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine
spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized
patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.
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Introduction
Chronic obstructive pulmonary disease (COPD) and chronic
heart failure (CHF) are important causes of morbidity and
mortality worldwide, particularly in the elderly [1,2]. Despite the
fact that COPD and CHF present a major challenge for
healthcare providers and share common risk factors—in
particular, cigarette smoking—few studies have addressed the
association of CHF and COPD and its impact on patient
management and prognosis in well-characterized patient
cohorts [3].
Cigarette smoking is the major risk factor for COPD and
cardiovascular diseases. It causes systemic inflammation,
oxidative stress, increased circulating concentration of
inflammatory cytokines, and changes in endothelial functions.
Low-grade systemic inflammation has been proposed to be the
common substrate of chronic diseases such as COPD and
CHF, and thus it is a possible link between these diseases and
their comorbidities [4].
C-reactive protein (CRP) is the most established marker of
systemic inflammation, plays an important role in COPD [5],
and is involved, although to a lesser extent, also in CHF [6].
Recently, another acute phase inflammatory protein of the
pentraxin family (PTX3) has been proved to be linked to the
severity and prognosis of CHF [7]. PTX3 is a component of the
humoral arm of the innate immune system which, unlike CRP,
is produced also at the site of inflammation [7]. We speculated
that examining and comparing plasma levels of CRP and PTX3
might add information on the role of systemic inflammation in
COPD and CHF. As interleukin-1β (IL-1 β) is a pro-
inflammatory cytokine and one of the main inducer of PTX3 [7],
it was included in the cytokines to be measured. Since the
decoy receptor sIL-1RII plays a key role in downing the action
of IL-1 β [8], its plasma level has also been determined.
Recognition of comorbid heart failure in COPD patients and
of COPD symptoms in CHF patients is hampered by similarities
in signs and symptoms, in particular, dyspnea. Moreover, even
though it is well known that spirometry is essential to establish
the diagnosis of COPD, and echocardiography is essential for
the diagnosis of CHF, epidemiological data suggest an under-
use in clinical practice of both measurements in smokers [9].
Indeed, in most retrospective studies reporting the coexistence
of COPD and CHF, the diagnoses were not based on
spirometry and echocardiography [10,11]. Thus, the aims of
our study were 1) to assess the occurrence of CHF by
echocardiography in well-characterized, spirometrically
documented smokers with COPD; 2) to assess the occurrence
of COPD by spirometry in well-characterized smokers with
CHF; and 3) to assess the degree of systemic inflammation by
measuring circulating high-sensitive C-reactive protein (Hs-
CRP), PTX3, IL-1 β, and soluble type II receptor (decoy
receptor) of IL-1 (sIL-1RII) in both cohorts.
Materials and Methods
This was a two-center observational study.
Study Subjects
A total of 218 subjects were studied: 70 COPD patients, 124
CHF patients, and 24 healthy smokers. Patients aged ≥50
years who had a smoking history of ≥10 pack years were
enrolled at the Respiratory Unit of the University Hospital of
Modena and at the Heart Failure Centre of the University
Hospital of Ferrara, respectively, between July 2009 and
September 2010. The control group of 24 age-matched healthy
smokers (≥10 pack years) had no known cardiac or respiratory
diseases or symptoms and were recruited from the same
outpatient clinics.
COPD patients had been free from exacerbations for 4
weeks, and CHF patients had been on stable medication for 3
months.
The study conformed to the Declaration of Helsinki and was
approved by the institutional ethics committees of each
participating university hospital (Comitato Etico Provinciale di
Ferrara and Comitato Etico Provinciale di Modena). All
participants provided signed informed consent before
recruitment (ClinicalTrials.gov number, NCT01114386).
Demographic/morphological data and results from body
mass index (BMI), spirometry, Charlson comorbidity index, 6-
min walk test (6MWT), basic biochemistry, N-terminal pro-
hormone brain natriuretic peptide (NT-proBNP), HsCRP, PTX3,
IL-1 β, and sIL-1RII were obtained from all study participants.
COPD and CHF patients also underwent electrocardiography
and echocardiography. Subsets of data collected from patients
with CHF were reported previously [12].
Sample Collection
Blood samples were obtained from all study subjects for
assessment of plasma concentrations of PTX3, IL-1 β, and
sIL-1RII. Blood samples were centrifuged at 1,500 x g for 10
min at 7 °C. Plasma aliquots were stored at -80 °C until
assayed.
Clinical and Functional Assessment
Spirometry (Biomedin, Padova, Italy) and the 6MWT were
performed according to current international guidelines [13,14].
Echocardiography was carried out by following a standard
protocol that included the measurements and the validated
diagnostic criteria recommended by the European Society of
Echocardiology [2].
Measurements of PTX3, IL-1 β, and sIL-1RII
Plasma levels of PTX3 and sIL-1RII were measured by in-
house sandwich ELISA as previously described [15,16].
Detection limit was 100 pg/ml for PTX3 and 20 pg/ml for
soluble IL-1RII. No cross-reaction with human CRP or serum
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amyloid P component was observed for antibodies used to
detect PTX3.
Plasma level of IL-1 β was determined using commercially
available kits (Quantikine HS High Sensitive ELISA [R&D
Systems, Minneapolis, MN]). Sensitivity was 0.057 pg. /ml.
The concentration of all cytokines was determined by
comparison with a standard curve, following the manufacturer's
instructions.
Statistical Analysis
The Shapiro–Wilk test was used to test the normal
distribution of continuous variables. When continuous variables
were normally distributed, the results were expressed as mean
± SD; otherwise, median and interquartile range (IQR; 25th-
75th percentile) were reported. Categorical variables were
summarized as counts and percentages. Continuous variables
were compared among groups (COPD patients, CHF patients,
and healthy smokers) by ANOVA if normally distributed and by
the Kruskal-Wallis test if non-normally distributed, with
Bonferroni corrections for multiple testing. Categorical variables
were compared among groups by the chi-square test or
Fisher’s exact test, when appropriate. Correlation between
continuous variables was assessed by using Spearman's rho.
An ANOVA on ranks was constructed to compare IL-1β and
sIL-1RII values among groups by considering potential
confounders. P values <0.05 (two sided) were considered
significant. Statistical analyses were performed using Stata
version 12 (StataCorp LP, College Station, TX, USA).
Results
Clinical and Functional Characteristics of Study
Groups
Seventy COPD patients, 124 CHF patients, and 24 healthy
smokers (control subjects) were studied (Tables 1 and 2). CHF
patients were slightly, but significantly older than both control
subjects and patients with COPD. The percentages of males,
BMI values, and number of pack years were similar in the three
groups. Of the CHF patients, 86% were classified as New York
Heart Association (NYHA) class I or II, and 63% of COPD
patients were classified as GOLD stage I or II (Table 1). In the
CHF group, 13 patients (11%) were treated with inhaled
bronchodilators and 10 (8%) were treated with inhaled steroids
(Table 1), as 34% of the CHF patients had airflow limitation. Of
the CHF patients with airflow limitation, 52% were classified as
GOLD stage I, 40% as GOLD II, and 8% as GOLD III. Patients
with pure COPD had a higher 6MWT, a lower Charlson
comorbidity index, a lower NT-proBNP, and a higher Hs-CRP
compared with all the CHF patients (Table 2). None of the
COPD patients showed impaired left ventricular systolic
function (left ventricular ejection fraction [LVEF] ≤ 40%) or a left
ventricular (LV) diastolic dysfunction. Likewise, we did not find
levels of estimated systolic pulmonary artery pressure
consistent with pulmonary hypertension. As mentioned above,
34% of CHF patients had airflow limitation. Partial arterial
pressure of oxygen (PaO2) was higher and partial arterial
pressure of carbon dioxide (PaCO2) was lower in CHF than in
COPD (82.7 ± 10.9 vs. 75.1 ± 9.3 mm Hg, p < 0.001, and 38.8
± 3.7 vs. 40.9 ± 4.5 mm Hg, p = 0.004, respectively). It is
noteworthy that, while all the COPD patients underwent this
measurement, 40% of the patients with CHF refused to perform
it.
Hypertension (98%), myocardial infarction (58%), and
hypercholesterolemia (35%) were the three most common
comorbidities in CHF patients, whereas hypertension (50%),
osteoporosis (14%), and diabetes (13%) were most common in
COPD patients.
PTX3, IL-1 β, and sIL-1RII
The plasma levels of PTX3 were similar in the three groups
studied; in contrast, circulating IL-1 β was higher in COPD
patients than in both CHF patients and control subjects
(healthy smokers; p < 0.001). Plasma levels of IL-1 β did not
differ between CHF patients and control subjects (Figure 1).
Likewise, sIL-1RII systemic concentrations were significantly
elevated in COPD compared to both CHF patients and control
subjects (p < 0.05 and p < 0.01, respectively) (Figure 1).
The potential correlations of PTX3, IL-1 β, and sIL-1RII with
clinical variables (age, BMI, smoking pack years, GOLD stage,
NYHA class, Charlson index, 6MWT, LVEF, NT-proBNP, Hs-
CRP, FEV1 [% predicted], FEV1/FVC [forced vital capacity],
Table 1. Clinical characteristics of COPD patients, CHF
patients, and healthy smokers (control subjects).
 COPD CHF Healthy smokers
 (n=70) (n=124) (n=24)
Age, yr* 68.7 ± 7.8 71.6 ± 6.9 67 ± 7.7
Males, n (%) 52 (74) 106 (86) 15 (62.5)
BMI, kg/m2 27.6 ± 4.6 28.1 ± 3.6 27 ± 5
Pack years 45.3 ± 27.1 41.8 ± 25.2 35.8 ± 15.4
GOLD stage, n (%)    
I 10 (14) - -
II 34 (49) - -
III 26 (37) - -
NYHA class, n (%)    
I - 26 (21) -
II - 81 (65) -
III - 15 (12) -
IV - 2 (2) -
Medication, n (%)    
ACE inhibitors 19 (27.5) 85 (68.5) 0
Beta blockers 14 (20) 103 (83) 0
Statins 20 (30) 79 (64) 0
Inhaled bronchodilators 57 (81) 13(11) 0
(LABA and/or LAMA)    
Inhaled steroids 43 (61) 10 (8) 0
Data are expressed as number of subjects (%) or mean ± SD.
Abbreviations: COPD, chronic obstructive pulmonary disease; CHF, chronic heart
failure; BMI, body mass index; NYHA, New York Heart Association; GOLD, Global
Initiative for Chronic Obstructive Lung Disease; ACE, angiotensin-converting
enzyme; LABA, long-acting beta agonists; LAMA, long-acting muscarinic agonists;
* Significant (p < 0.05): COPD vs. CHF, and CHF vs. healthy smokers.
doi: 10.1371/journal.pone.0080166.t001
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and statin, inhaled bronchodilator and inhaled steroid
treatments) were checked. PTX3 and sIL-1RII did not show
clinically meaningful associations with any of those parameters.
IL-1 β correlated negatively with NT-proBNP (rho = -0.34, p <
0.001), FEV1 (% predicted) (rho = -0.29, p < 0.01), and
FEV1/FVC (rho = -0.35, p < 0.001), and correlated positively
with Hs-CRP (rho = 0.30, p < 0.01).
Finally, an ANOVA on ranks was constructed to compare
either IL-1 β or sIL-1RII values among groups, considering
potential confounders such as age, smoking, pack years, NT-
proBNP, Hs-CRP, FEV1 (% predicted), FEV1/FVC, and statin,
inhaled bronchodilator and inhaled steroid medication. IL-1 β,
but not sIL-1RII, remained significantly higher in COPD patients
than in CHF patients and healthy smokers [1.43 (0.57-2.16) vs.
0.48 (0.34-0.88) and 0.47 (0.40-0.89, respectively, p < 0.0006].
Table 2. Functional characteristics of COPD patients, CHF




 (n=70) (n=124) (n=24)  
Charlson
comorbidity index
1 (1–2) 3 (2–4) - < 0.001
6MWT, m 490 ± 131 378 ± 163 N.A. < 0.001
LVEF (%) 69.83 ± 7.04 40.45 ± 11.59 N.A. < 0.001
NT-proBNP, pg/ml 115 (50–364)
984 (450–
2095)






























Data are expressed as mean ± SD or median value (interquartile range: 25th–75th
percentile).
Abbreviations: 6MWT, 6-min walk test; LVEF, left ventricular ejection fraction; NT-
proBNP, N-terminal pro-hormone of brain natriuretric peptide; Hs-CRP, high-
sensitive C-reactive protein; BD, bronchodilator; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; N.A., not available.
* Significant (p < 0.05) post-hoc tests: COPD vs. CHF; COPD vs. healthy smokers;
CHF vs. healthy smokers.
** Significant (p < 0.05) post-hoc tests: COPD vs. CHF; COPD vs. healthy
smokers.
*** Significant (p < 0.05) post-hoc tests: COPD vs. CHF; COPD vs. healthy
smokers; CHF vs. healthy smokers.
Significant (p < 0.05) post-hoc tests: COPD vs. CHF; COPD vs. healthy smokers;
CHF vs. healthy smokers.
Significant (p < 0.05) post-hoc tests: COPD vs. CHF; COPD vs. healthy smokers;
CHF vs. healthy smokers.
doi: 10.1371/journal.pone.0080166.t002
Discussion
Although we detected no echocardiographically documented
CHF in well characterized smokers with COPD, we found
airflow limitation in 34% of well-characterized smokers with
CHF. Furthermore, we found evidence of low-grade systemic
inflammation only in patients with COPD.
The finding of 34% airflow limitation in smokers with CHF is
consistent with previously reported prevalences of COPD in
patients with heart failure, ranging from 10 to 50% [17]. The
prevalence of airflow limitation in our study was based on post-
bronchodilator spirometry, whereas most of the previous
studies were retrospective and COPD diagnosis was self-
reported [10,11]. Notably, only 10 of our 42 patients with both
CHF and COPD were aware of airflow limitation and were
properly treated, highlighting the importance for better
screening for this comorbidity in CHF patients [11].
Spirometry may be difficult to assess in elderly patients with
CHF, and diagnosis of COPD may be under- or over-estimated
in these patients. Spirometric abnormalities of the restrictive
type may be present in patients with stable heart failure, and
airflow limitation may develop in patients with decompensated
heart failure [17]. Also, FEV1/FVC ratio might overestimate
airflow limitation and thus over-diagnose COPD particularly in
the elderly [18]. The “restrictive” abnormality might “mask”
airflow limitation in stable CHF and thus cause under-
estimation of airflow limitation and consequently
underdiagnosis of COPD. By contrast, the transient airflow
limitation might cause over-estimation of airflow limitation and
consequently overdiagnosis of COPD in decompensated CHF.
Even considering these limits of spirometry, it should be
mentioned that spirometry is just one criterium for establishing
the clinical diagnosis of COPD, the others being symptoms and
risk factors (http://www.goldcopd.org/.). Because the CHF
subjects we examined were stable and were all smokers, we
feel rather confident that the risk of misdiagnosis in this group
of patients with CHF is limited.
We did not observe any overt LV systolic dysfunction (ie
LVEF ≤40%) in COPD patients. Also LV end-diastolic size and
LV end-systolic size were not abnormal in any but one patient
with COPD, who had definitively increased LV end-diastolic
and end-systolic diameters, according to the normal values
indicated in the European Society of Cardiology guidelines for
the diagnosis and treatment of acute and chronic heart failure
[2]. The prevalence of left heart abnormalities previously
described in COPD patients varies widely, from 0 to 32%
[19,20], depending on whether the study was performed on
selected patients with no history of coronary heart disease or
on unselected subjects. In two recent studies, the prevalence
of overt LV systolic dysfunction was 17% and 13%,
respectively [20,21]. In the first survey [20], LV dysfunction
burden was concentrated in COPD patients classified as GOLD
III and IV (70%), with a significant proportion of subjects with
documented ischemic heart disease (40.5%) and with a
median value of NT-proBNP higher than that detected in our
COPD population (677 vs. 115 pg/ml). Therefore, our failure to
find left heart abnormalities might be explained by the different
characteristics of our COPD patients. In the second study [21],
COPD and CHF: Comorbidity and Systemic Mediators
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the prevalence of overt LV systolic disfunction (LVEF < 40%)
was < 4%, and the prevalence of impaired LV systolic function
was present in 13% of subjects, although most often the
impairment was mild (LVEF <0.50).
The high LVEF (%) observed in our COPD might be
explained by the following reasons: 1) patients with COPD
were recruited in tertiary pulmonary referral centers, and were
all on regular COPD pharmacologic treatment, and thus most
likely patients with COPD and chronic heart failure were
excluded from the recruitment; and 2) patients with COPD were
all treated with long-acting bronchodilators associated or not
with inhaled steroids, and thus the hemodynamic effects of the
bronchodilator therapy may have contributed to the high values
of LVEF. In fact both inhaled antimuscarinic and beta 2 agonist
bronchodilators increase ejection fraction and stroke volume
[22], 3) the result of a normal Nt-proBNP is consistent with the
finding of a normal LVEF and excludes definitively a diagnosis
of heart failure, either with reduced or preserved ejection
fraction. In reality, heart failure is unlikely in patients showing a
Nt-proBNP value less than 125 pg/ml, as reported in the
diagnostic flowchart for suspected heart failure of the 2012
European Society of Cardiology guidelines [2].
It has been hypothesized that chronic low-grade systemic
inflammation is a “common soil” for pulmonary and
cardiovascular diseases, particularly COPD and CHF, and that
aging, smoking, and obesity, the major risk factors for complex
chronic disorders, cause systemic inflammation.
The results presented here show that the serum level of Hs-
CRP was significantly higher in COPD patients than in CHF
patients and control subjects, which did not differ from each
other. The association between stable COPD and increased
blood CRP is well established and helps to explain the
presence of systemic inflammation in this chronic pulmonary
disease [5]. In contrast, the role of inflammation in the
pathogenesis of CHF is less well defined. There is evidence of
elevated CRP levels in patients with heart failure in higher
NYHA functional classes, with higher rates of hospital
readmission and higher rates of mortality [6]. Our finding of a
similar concentration of CRP in CHF patients and control
subjects could be explained, at least in part, by the fact that
Figure 1.  PTX3 (A), IL-1β (B), and sIL-1RII (C) plasma levels in COPD, CHF and healthy smokers.  IL-1β and sIL-1 RII plasma
levels were significantly higher in COPD than in both CHF patients and control subjects (healthy smokers). PTX3 plasma levels did
not differ among the three groups.
Data are expressed as the median value; bars indicate the 75th and 25th percentiles.
○ p<0.001, COPD vs. CHF, and COPD vs. healthy smokers.
*; p<0.05, COPD vs. CHF ; ** p<0.01, COPD vs. healthy smokers.
doi: 10.1371/journal.pone.0080166.g001
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most of the CHF patients in our study had stable, mild disease
(NYHA classes I and II).
CRP is a member of the pentraxin superfamily. In recent
years, another pentraxin, PTX3, has been investigated in both
CHF and COPD. In CHF, PTX3 is related to more severe
disease and worse outcomes, such as all-cause mortality,
cardiovascular mortality, and hospitalization for
decompensated heart failure [7]. Our study complements these
previous observations by showing that the PTX3 plasma level
of a cohort with mild symptomatic heart failure (NYHA classes I
and II) and clinically stable heart failure is similar to that of
healthy subjects matched for age and smoking history. With
regard to COPD, we confirmed the earlier finding of circulating
levels of PTX3 within the normal range [23].
IL-1 β, a proinflammatory cytokine, is increased in airway
secretion during exacerbation of COPD [24,25] and correlates
significantly with other inflammatory mediators and cells when
COPD is stable [26]. Our finding of higher plasma
concentrations of IL-1 β in COPD compared to control subjects
(healthy smokers) is in agreement with the results of previous
studies focused on profiling serum biomarkers in patients with
stable COPD [27]. In contrast, this finding may appear to
conflict with that of Sapey et al. [28], who found no differences
in circulating IL-1 β between COPD patients and healthy
subjects. However, they examined very few patients (n=15)
and compared them with control subjects who had never
smoked, making it impossible to distinguish between the effect
of smoking and the effect of COPD.
Recent studies indicate that decoy receptors act as a general
strategy to fine-tune the action of primary inflammatory
mediators. The decoy receptor paradigm describes a receptor
that is capable of recognizing its ligand with high affinity and
specificity, but that is structurally incapable of signaling [29].
Soluble IL-1RII was the first pure decoy receptor to be
identified, and, in the current study, we have shown that its
systemic level is higher in COPD patients than in both control
subjects and CHF patients. This increase may indicate an
attempt to prevent the inflammatory biological effects mediated
by the elevated IL-1 β in COPD patients. However, other
investigations are better suited to clarify the role of sIL-1RII in
COPD [28,30].
Circulating IL-1 β and sIL-1RII levels did not differ between
our CHF patients and control subjects. This was not completely
unexpected, as the inflammatory network in CHF is still
debated. In particular, previous studies have reported that IL-1
β systemic levels in heart failure are either unchanged [31],
increased [32], or decreased [33]compared to controls.
In conclusion, this report shows that airflow limitation is
common and unrecognized in smokers with CHF, whereas a
consistent impairment of LV function is not always detectable in
well-characterized patients with COPD. In contrast to CHF
patients, COPD patients show evidence of low-grade systemic
inflammation, as demonstrated by an increase in CRP, IL-1 β,
and sIL-1RII plasma levels. Better clinical and functional
characterization of elderly smokers with chronic diseases, and
identification of the key inflammatory mediators involved, may
help to improve the treatment and management of these
patients.
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